nucleosidetid
analog
need
transform
tp
exert
ontarget
offtarget
effect
tp
form
necessari
elucid
mechan
tabl
typic
initi
enzymat
assay
polymeras
radioactivitybas
polymer
assay
inhibit
nucleotid
measur
valu
inhibit
assay
easili
adapt
filter
bind
assay
multipl
compound
access
simultan
howev
base
inhibit
studi
alon
one
establish
whether
nucleotid
actual
incorpor
therefor
singl
nucleotid
incorpor
sni
assay
particularli
use
determin
ntp
analog
actual
serv
substrat
polymeras
high
concentr
ntp
analog
eg
ribos
nucleotid
tp
rntp
nucleotid
tp
dntp
rel
rate
incorpor
analog
compar
natur
ntp
counterpart
mechanist
insight
presteadi
state
kinet
analysi
ntp
incorpor
offer
detail
kinet
paramet
presteadi
state
polymer
rate
constant
kpol
ntp
dissoci
constant
kd
studi
incorpor
rate
studi
use
multipl
time
point
nucleotid
concentr
often
use
quenchflow
techniqu
make
studi
reagent
timeconsum
final
mechan
nucleotid
analogderiv
enzym
inhibit
reveal
elong
assay
stabl
elong
complex
form
incorpor
next
natur
ntp
measur
normal
ntp
analog
character
one
three
group
chaintermin
delay
chaintermin
stabli
incorpor
analog
stabli
incorpor
ntp
analog
difficult
studi
toxic
could
lead
littl
quantit
chang
dna
rna
protein
qualiti
abovement
biochem
assay
reli
heavili
avail
high
qualiti
tp
activ
form
time
resourceconsum
synthes
tp
salt
subject
degrad
overtim
time
certain
inorgan
contamin
could
lead
appar
inhibit
polymeras
due
mechan
action
nucleosid
analog
gener
evalu
day
replic
laboratoryadapt
cell
line
nonrepl
primari
standard
readout
effect
compound
atp
level
within
cell
found
among
laboratoryadapt
cell
test
prostat
cancerderiv
cell
tcell
leukemiaderiv
cell
gener
sensit
toxin
significantli
sensit
cell
wide
use
cell
line
vitro
toxic
studi
addit
found
laboratoryadapt
cell
use
detect
potenti
toxic
liabil
primari
cell
certain
case
test
specif
cell
assay
warrant
exampl
number
firstgener
hiv
nucleosid
analog
show
myelosuppress
effect
result
fda
recommend
evalu
toxic
growth
human
bone
marrow
progenitor
cell
coloni
format
nucleosidetid
analog
cytotox
often
directli
relat
cellular
level
activ
tp
metabolit
guanosin
nucleotid
prodrug
former
form
higher
tp
correl
significantli
higher
nucleosid
analog
poorli
phosphoryl
cell
balapiravir
even
though
specif
inhibitor
polrmt
balapiravir
show
littl
toxic
larg
panel
cell
line
primari
cell
test
develop
compound
stop
phase
ii
due
toxic
shown
tabl
employ
three
mitochondriafocus
cellbas
assay
evalu
potenti
mitochondri
toxic
mitochondri
dna
content
assay
wide
use
studi
nucleosid
analog
assess
effect
ribos
nucleosidetid
analog
mitochrondri
rna
ddc
serv
good
posit
control
cell
seem
ideal
cell
line
assay
mitochondri
protein
synthesi
assay
use
evalu
ribonucleosidetid
analog
assay
level
two
protein
measur
simultan
mitochondri
dnaencod
protein
cytochrom
c
oxidas
nuclear
dnaencod
protein
succin
dehydrogenas
sdha
data
analysi
found
compar
individu
level
sdha
protein
untreat
dmso
control
yield
reproduc
data
use
ratio
sdha
chloramphenicol
specif
inhibitor
mitochondri
protein
synthesi
use
posit
control
sinc
mitochondri
respir
regard
gold
standard
measur
mitochondri
use
extens
studi
mitochondri
toxin
directli
impair
electron
transport
chain
use
studi
nucleosidetid
analog
assay
provid
sensit
function
readout
requir
knowledg
mechan
complet
loss
mitochondri
respir
capac
detect
chang
cellular
atp
level
phenomenon
observ
inhibitor
divers
molecular
target
includ
ddc
inhibitor
mitochondri
dna
synthesi
cytidin
inhibitor
mitochondri
rna
synthesi
chloramphenicol
inhibitor
mitochondri
protein
synthesi
compound
show
mitochondri
gener
toxic
method
make
possibl
identifi
whether
mitochondria
toxic
occur
lower
drug
mitochondri
protein
respir
assay
found
cell
offer
higher
sensit
reproduc
face
mitochondria
damag
cell
known
switch
glycolysi
gener
atp
therefor
assay
wide
use
detect
mitochondria
absenc
glucos
galactoseadapt
cell
forc
reli
heavili
mitochondri
oxpho
thu
would
show
decreas
howev
predict
assay
challeng
hyne
report
show
assay
detect
potenti
mitochondri
toxin
even
though
nucleosidetid
analog
includ
hyne
studi
consist
find
test
clinic
relev
nucleosidetid
analog
none
known
mitochondri
toxin
ddc
fiau
c
show
enhanc
cytotox
galactoseadapt
cell
research
develop
signific
number
nucleosidetid
analog
termin
preclin
stage
due
toxic
anim
model
though
mitochondri
toxic
indic
suspect
date
due
number
factor
outlin
mitochondri
toxic
difficult
detect
anim
speci
correl
human
best
potenti
anim
model
genet
mitochondri
abnorm
human
anim
may
sensit
nucleosidetid
toxic
exampl
mice
model
genet
mitochondri
abnorm
heterozyg
superoxid
dismutas
knockout
mice
suscept
mitochondria
toxin
wildtyp
recent
xu
et
al
report
fiauinduc
liver
toxic
chimer
tknog
mice
graft
human
anim
model
like
may
improv
abil
detect
nucleosid
toxic
viral
diseas
vari
greatli
durat
sever
safeti
threshold
antivir
nucleosidetid
need
consid
context
efficaci
treatment
durat
exampl
compound
treat
acut
deadli
viral
infect
ebola
would
like
differ
safeti
criteria
drug
use
control
chronic
infect
hbv
exist
nucleosidetid
routin
screen
emerg
virus
possibl
compound
fail
achiev
adequ
therapeut
window
one
viru
may
suitabl
treat
viral
infect
antivir
nucleosidetid
analog
target
viral
dna
rna
replic
machineri
mechan
make
potenti
inhibitor
host
dna
rna
synthesi
well
especi
mitochondri
dna
rna
synthesi
mitochondri
toxic
manifest
multipl
form
vivo
underli
mani
clinicalstag
failur
difficult
detect
anim
studi
past
year
batteri
vitro
test
mitochondri
toxic
evolv
continu
expand
allow
improv
earli
detect
mitochondri
liabil
drug
molecul
actual
toxic
liabil
assess
fulli
test
anim
toxic
studi
eventu
human
clinic
trial
nevertheless
believ
employ
proper
biochem
cellular
assay
earli
meaning
impact
reduc
preclin
clinic
toxic
liabil
class
compound
